A new analysis to be presented at this year’s European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12-15 May) examined daily oral orforglipron treatment for the treatment of obesity, with or without diabetes, in users aged 65 years and over, with results and a safety profile similar to that seen in the ATTAIN clinical trial programme population. Lead author for this post-hoc analysis is Dr Deborah Horn, Director of the Center for Obesity Medicine and Metabolic Performance at McGovern Medical School at UTHealth Houston, Houston, Texas, USA, and colleagues.

About The Study: Treatment with digitalis glycosides was associated with a lower risk of the composite of cardiovascular death or first worsening heart failure (HF) event in patients with heart failure with mildly reduced ejection fraction (HFmrEF) or heart failure with reduced ejection fraction (HFrEF), mainly through a lower risk of worsening HF events. There was no statistically significant interaction with important study characteristics, including the extent of HF background therapy or type of digitalis glycosides treatment. These results suggest digitalis glycosides may be used as additional medical therapy to reduce worsening HF events in patients with HFmrEF or HFrEF.

About The Study: In patients with symptomatic rheumatic heart disease, digoxin reduced the risk of a composite of all-cause death or new-onset or worsening heart failure, with little risk of toxicity. This study is being published to coincide with the European Society of Cardiology Heart Failure 2026 Congress.

New research being presented at this year’s European Congress on Obesity (ECO 2026) in Istanbul, Turkey (12-15 May) and published in International Journal of Environmental Research and Public Health shows that doing around 8,500 steps a day can help people keep weight off after dieting.

University of Warwick real-time study shows how ‘mental defeat’ drives suffering and causes people with chronic pain to withdraw from everyday activities.

Aging is a complex process, and precisely measuring how the human body declines has long been a challenge. Two people of the same chronological age can have very different health trajectories. Scientists have also struggled to move beyond identifying aging markers to pinpointing what actually drives aging itself. Now researchers from China’s Aging Biomarker Consortium (ABC) have built a computational framework—the Digital Aging Twin—to study aging at the individual level in order to predict biological age and track the different aging rates of individual organs.